Probing the Histamine H<sub>1</sub> Receptor Binding Site to Explore Ligand Binding Kinetics
Analysis of structure-kinetic relationships (SKR) can contribute to an improved understanding of receptor-ligand interactions. Here, fragment <b>1</b> (4-(2-benzylphenoxy)-1-methylpiperidine) was used in different fragment growing approaches to mimic the putative binding mode of the long residence time (RT) ligands olopatadine, acrivastine, and levocetirizine at the histamine H<sub>1</sub> receptor (H<sub>1</sub>R). SKR analyses reveal that introduction of a carboxylic acid moiety can increase RT at H<sub>1</sub>R up to 11-fold. Ligand efficiency (LE) decreases upon the introduction of the negatively charged group, whereas kinetic efficiency (KE) increases up to 8.5-fold. The olopatadine/acrivastine mimics give up to 15-fold differences in the RT, while the levocetirizine mimics afford similar RTs with only a 3-fold difference. Therefore, the levocetirizine mimics are less sensitive to structural changes. This study illustrates that for H<sub>1</sub>R, there are several ways to increase RT but the different strategies differ significantly in SKR.
Authors
- Sebastiaan Kuhne
- Chris de Graaf (ORCID: https://orcid.org/0000-0002-1226-2150)
- Albert J. Kooistra (ORCID: https://orcid.org/0000-0001-5514-6021)
- Iwan J. P. de Esch (ORCID: https://orcid.org/0000-0002-1969-0238)
- Henry F. Vischer (ORCID: https://orcid.org/0000-0002-0184-6337)
- Reggie Bosma (ORCID: https://orcid.org/0000-0003-3591-1376)
- Maikel Wijtmans (ORCID: https://orcid.org/0000-0001-8955-8016)
- Rick Riemens
- Rob Leurs (ORCID: https://orcid.org/0000-0003-1354-2848)
- Marc C. M. Stroet
Institutions
- Vrije Universiteit Amsterdam (NL)
Publication Details
- Journal
- Journal of Medicinal Chemistry
- Published
- 2024-12-26
- DOI
- https://doi.org/10.1021/acs.jmedchem.4c02043
- Citations
- 2
- Primary Topic
- Receptor Mechanisms and Signaling
- Type
- article
- Field-Weighted Citation Impact
- 0.47
Funders
- European Cooperation in Science and Technology
- Innovative Medicines Initiative